Dianthus therapeutics to host conference call and webcast to discuss results from phase 2 magic trial of claseprubart (dnth103) in generalized myasthenia gravis

New york and waltham, mass., sept. 07, 2025 (globe newswire) -- dianthus therapeutics, inc. (nasdaq: dnth), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced a conference call and webcast to discuss results from the phase 2 magic trial of claseprubart (dnth103) in generalized myasthenia gravis (gmg) scheduled for tomorrow, monday, september 8, 2025 at 8:00 a.m. edt.
DNTH Ratings Summary
DNTH Quant Ranking